---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-125196"
form_type: "8-K"
ticker: "PRPO"
cik: "0001043961"
company_name: "Precipio, Inc."
filed_at: "2026-11-10T21:15:38+00:00"
generated_at: "2026-11-10T21:17:27.900692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Precipio Q3-2026 revenue $7.3M, up 8% YoY to a record; Adjusted EBITDA $0.4M, operating cash flow $0.6M

## Summary
- Revenue $7.3M, up 8% YoY from $6.8M in Q3-2025 and above $7.0M in Q2-2026; product revenue $1.0M (+40% YoY), pathology revenue $6.3M (+5% YoY).
- Adjusted EBITDA $0.4M vs $0.5M in Q3-2025 and $0.4M in Q2-2026; GAAP net income was roughly $0.0M versus a $0.1M net loss a year earlier.
- Cash flow from operations $0.6M; total cash rose $0.5M to over $3.5M at September 30, 2026, versus $2.3M in Q3-2025.
- CEO Ilan Danieli said pathology provides the financial foundation for growth and serves as the clinical validation platform for proprietary diagnostic products.
- Management hosted a shareholder call at 5 PM ET on November 10, 2026; full results are in the Form 10-Q filed the same day.

## SEC filing metadata
- accession: 0001104659-26-125196
- form_type: 8-K
- ticker: PRPO
- cik: 0001043961
- company_name: Precipio, Inc.
- filed_at: 2026-11-10T21:15:38+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1043961/000110465926125196/0001104659-26-125196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1043961/000110465926125196/tm2629335d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-125196
- JSON: https://secwatch.observer/filing/0001104659-26-125196.json
- Plain text: https://secwatch.observer/filing/0001104659-26-125196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.